SSRI CHINA news

Kio and Levis (from HIMA – an SSRI group company) attend the 5th China Pharma Decision Science Summit and CphMRA 2014 Annual Meeting in Yangzhou.

Photo courtesy of CMRA

SSRI (Social Survey Research Information Co., LTD.) and SSRI CHINA releases its first China market report – "Type 2 Diabetes Market in China", which covers information such as current patient loads, treatments used and its satisfaction levels, awareness of pre-launched products, sales rep activity, information sources, and future forecast.

This report is based on the findings from an online survey conducted with 200 respondents (half specialists and half non-specialists), from tier 1 and tier 2 cities, practicing in tier 2 and tier 3 hospitals.

• Diabetologists in China treat on average 324 T2D patients a month.
• Most commonly used 1st line therapy for T2D in China is biguanides.
• Within the OADs, biguanides has the highest satisfaction rate.
• Glucophage (metformin) has the highest usage rate.
• Respondents believe the number of diabetes patients in China will increase 1.4 times in 10 years.
• "Albiglutide" is the most recognized product within products not yet available in China
• Bayer has the highest sales rep visitation rate.
• Sales reps are not evaluated highly as an important information source relating to diabetes.

For more information, please contact:

SSRI (Tokyo):
Mr. Chao Xue
cxue@ssri.com
Tel: +81 03-3370-3474

SSRI China:
Ms. Jane Zhang
zhangjun@ssrichina.com
Tel: +86 411-3966-9060